Industry News
Biotechnology Industry News
Moderna, an mRNA specialist known…
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.
Pfizer has released the full data…
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.
Genetic medicines outfit Ensoma is…
Genetic medicines outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions.
Facing skepticism from analysts…
Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.
Novartis may have signed off on…
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.
Aspen Neuroscience’s cash…
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.
GSK has picked a novel protein…
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.
Merck KGaA has become the latest…
Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to
Stegeman says decentralized trial…
Stegeman says decentralized trial models improve access, diversity and patient retention
After laying off 80% of staffers…
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company.
Quest Diagnostics emphases the…
Quest Diagnostics emphases the critical role of in vitro diagnostics (IVDs) in shaping modern healthcare and advancing precision medicine.
Korea’s Celltrion is continuing…
Korea’s Celltrion is continuing to move beyond biosmilars, this time securing the option to use TriOar’s antibody platform in a deal potentially worth more than $350 million.
Merck & Co. has reported…
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.
CEO Paul Stoffels has left, and…
CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?
GSK has paid $50 million upfront…
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
As the biopharma world…
As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening of a new Gateway Labs site, this time in Philadelphia.
Clinical trials succeed or stall…
Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. The science of the trial may be sound and the protocol may be innovative, but
On its face, there wasn’t much…
On its face, there wasn’t much notable about Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio). A $1.15 billion upfront payment to secure a phase 3-ready monoclonal antibody is chump change in the broader
Vanda Pharmaceuticals’ expansion…
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase
This year saw attendance jump…
This year saw attendance jump again, with an estimated 4,500 people from 50 countries and across 950 healthcare companies set to show up.